Background: PRMT6 (protein arginine methyltransferase 6) regulates gene transcription via its ability to methylate histones H3 and H4. Results: Product and dead-end inhibition experiments were performed to assign the kinetic mechanism of PRMT6. Conclusion: PRMT6 utilizes a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes. Significance: This information should aid in the development of inhibitors targeting PRMT6, which may represent novel cancer therapeutics.
Over the last decade, the protein arginine methyltransferases (PRMTs) 2 have emerged as an enzyme family whose activity is dysregulated in human disease (1) (2) (3) (4) . The PRMTs catalyze the mono-and dimethylation of peptidylarginine residues in a variety of substrates to maintain cellular processes, e.g. cellular growth and signaling, nuclear-cytoplasmic protein shuttling, cell differentiation, embryogenesis, transcriptional regulation, and chromatin remodeling (5) (6) (7) (8) . There are three main types of PRMTs. The type I isozymes (PRMT1-4, PRMT6, and PRMT8) generate monomethylarginine (MMA) and asymmetric dimethylarginine (ADMA); the type II isozyme (PRMT5) generates MMA and symmetric dimethylarginine; and the type III isozyme (PRMT7) generates only MMA (2) . 3 Given that this family of enzymes plays an integral role in many cellular processes, it is not surprising that, when dysregulated, these enzymes also contribute to human disease. For example, aberrantly increased PRMT activity is associated with heart disease via its ability to generate free ADMA; high levels of ADMA have been linked to heart disease and renal failure (3, 9 -13) . Additionally, PRMT1 activity appears to be increased in breast cancer (13) . PRMT6, the focus of the studies reported herein, has also been reported to be overexpressed in, and to be required for, the proliferation of bladder and lung cancer cells (14) . Interestingly, siRNA knockdown of PRMT6 in U2OS osteosarcoma cells led to the up-regulation of thrombospondin-1, a natural inhibitor of angiogenesis and cell migration (15) . Thus, the PRMTs represent interesting therapeutic targets.
As a part of a program focused on developing inhibitors targeting the PRMTs, we initiated studies to characterize the catalytic mechanisms, substrate specificity, and kinetic mechanisms of these enzymes (16 -19) . Previous studies with PRMT1 have shown that this isozyme preferentially methylates substrates with positively charged residues distal to the site of methylation (16) . Additionally, we demonstrated that PRMT1 catalyzes ADMA formation in a partially processive fashion, i.e. a fraction of the monomethylated product remains bound to the enzyme, whereas S-adenosyl-L-homocysteine (SAH) is exchanged for S-adenosyl-L-methionine (SAM) to allow for a second round of methylation (16) . Consistent with this mechanism, we showed that PRMT1 uses a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes (16, 17) . Information from these studies guided the development of C21, an irreversible inhibitor that is the most potent and selective PRMT1 inhibitor described to date (19) . Although this compound shows excellent selectivity (Ͼ100-fold) versus PRMT3 and PRMT4, it is only modestly selective for PRMT6 (19) . In an effort to improve the selectivity of C21, we initiated studies to characterize the molecular mechanisms of PRMT6 catalysis.
PRMT6 catalyzes the methylation of several proteins, including histones H3 and H4, and this activity has been shown to play a key role in controlling the expression of the HOX genes as well as Myc-dependent genes (20, 21) . Previously, PRMT6 was shown to also catalyze the methylation of the R1 and R1-MMA peptides, which contain a single arginine residue (22) . The R1 peptides are based on the amino acid sequence of an internal portion of fibrillarin, a known protein substrate of PRMT6 (23) . Although PRMT6 was reported to utilize a steady-state ordered mechanism in which SAM binds to the enzyme prior to protein or peptide (Scheme 1) (22), we show here that the IC 50 values of C21, an irreversible PRMT6 inhibitor, are similar, regardless of whether C21 is preincubated with the enzyme in the absence or presence of SAM. This result suggested that SAM binding is not required for inhibitor/peptide binding and thus called into question the assignment of an ordered mechanism for this enzyme. Therefore, we reinvestigated the kinetic mechanism of PRMT6. These studies revealed that PRMT6 utilizes a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes (Scheme 2). PerkinElmer Life Sciences, and 14 C-labeled BSA was purchased from American Radiolabeled Chemicals. A pET16 vector encoding the human DNA sequence of PRMT6 was obtained from Mark T. Bedford (The University of Texas MD Anderson Cancer Center). The purification of PRMT6 is described under supplemental "Methods." Peptides were synthesized on Wang resin using standard Fmoc chemistry and purified by reverse phase HPLC. The sequences of the peptides used in these studies, as well as their expected and observed masses, are provided in Table 1 . All mass spectra were acquired by MALDI-MS.
EXPERIMENTAL PROCEDURES
Gel-based Activity Assay-Activity assays were performed as described previously for PRMT1 using a discontinuous gelbased assay (16) . The assay buffer consisted of 50 mM HEPES (pH 8.0), 50 mM NaCl, 1 mM EDTA, and 0.5 mM DTT. Generally, enzyme assays were performed by first preincubating the assay buffer with SAM and peptide substrate for 10 min at 37°C and then initiating the reaction by the addition of PRMT6 (500 nM final concentration). The reaction was quenched after 15 min with 6ϫ Tris/Tricine gel loading dye. Under these conditions, PRMT6 activity is linear with respect to both time and enzyme concentration. All assays were performed at least in duplicate, and the S.D. was Յ20%. Where appropriate, the initial rates obtained from these assays were fit by nonlinear least squares analysis to Equation 1 using the GraFit Version 5.0.11 software package (24) . where [I] is the concentration of inhibitor, and IC 50 is the concentration of inhibitor that yields half-maximal activity. SCHEME 1. Ordered sequential mechanism. In the ordered sequential mechanism, reported by Lakowski and Frankel (22) , SAM binds to the enzyme, and subsequent binding of the peptide substrate generates a ternary complex. Following product formation, ADMA is released from the enzyme before SAH to regenerate the free enzyme. A, SAM; B, peptide substrate; P, ADMA; Q, SAH. SCHEME 2. Rapid equilibrium mechanism with dead-end EAP and EBQ complexes. In the PRMT6-catalyzed reaction, the substrates bind to the enzyme in a random fashion to generate a ternary complex. Upon formation of the ternary complex, the reaction products are released in a random fashion to regenerate the free enzyme. Dead-end complexes, EAP (enzyme⅐ MMA⅐SAH) or EBQ (enzyme⅐SAM⅐ADMA), can be formed when either reaction product, SAH or the ADMA-containing peptide, binds to the enzyme after the first substrate binds or after the first product has been released from the ternary complex. A, MMA; B, SAM; P, SAH; Q, ADMA. Initial Velocity Studies-Initial velocity patterns were obtained by determining the steady-state kinetic parameters for a substrate at different fixed concentrations of the second substrate. The initial rates for substrate peptides were determined at different fixed concentrations of [ 14 C]SAM (2.5, 5, and 10 M for AcH4-21; 2.5, 5, and 10 M for AcH4-21R 3 MMA; 2.5, 5, and 15 M for R1; and 2.5, 5, 10, and 15 M for R1-MMA). For SAM, initial rates were obtained at fixed concentrations of AcH4-21 (1, 2.5, and 5 M), AcH4-21R 3 MMA (2.5, 10, and 15 M), R1 (25, 50, 100, and 200 M), and R1-MMA (25, 50, 100, and 200 M). A global fit of the data was obtained by fitting the initial rate data to Equation 3 using the GraFit Version 5.0.11 software package (24),
where K ia is the dissociation constant of the varied substrate, and K a and K b are the Michaelis-Menten constants for the varied and fixed substrates, respectively.
Inhibition Studies-Product inhibition experiments were carried out using the assay methodology outlined above. For these experiments, either peptide product (i.e. the AcH4-21R 3 ADMA or R1-ADMA peptide) or SAH was used as the product inhibitor. Dead-end analog inhibition experiments were carried out analogously using the AcH4-21R 3 K or R1-R 6 K peptide and sinefungin as the dead-end analogs. Note that PRMT6 did not methylate the AcH4-21R 3 K or R1-R 6 K peptide to an appreciable extent (the k cat /K m values were decreased by at least 2-3 orders of magnitude; see Table 1 
where K ii is the intercept K i , and K is is the slope K i . Note that Equation 5 is the equation for pure noncompetitive inhibition, where
The best fits of the data to Equations 4 -7 were chosen using a combination visual inspection along with a comparison of the S.E. values.
RESULTS

Purification, Initial Kinetic Characterization, and Inhibition
Studies with C21-Recombinant PRMT6 was expressed in Escherichia coli and purified, via a combination of metal ion affinity and anion exchange chromatographies, in excellent yield (ϳ1 mg/liter). The steady-state kinetic parameters were then determined for the R1 and AcH4-21 peptides (Table 1) , and the results indicate that the AcH4-21 peptide is a significantly better substrate than the fibrillarin-based R1 peptide. Interestingly, the K m values reported previously for the R1 and R1-MMA peptides are ϳ4-fold higher than those found in our analyses, and the k cat values that were previously observed are ϳ4-fold lower than our calculated rates ( 11-fold higher than those reported previously. We believe that the difference is due at least in part to optimization of the enzyme purification procedure, as we have noted that deviation from this procedure leads to a rapid loss of enzyme activity.
C21 is a peptide-based inhibitor that is identical in sequence to the AcH4-21 peptide, except that Arg-3 is replaced with a chloroacetamidine-modified ornithine residue. This compound, which irreversibly inhibits the PRMTs, shows excellent selectivity (Ͼ100-fold) for PRMT1 versus PRMT3 and PRMT4 but is only modestly selective for PRMT6 (19) . Interestingly, the IC 50 values of C21 for PRMT6 are similar regardless of whether the reaction is initiated by the addition of SAM or AcH4-21 (2.1 Ϯ 0.1 versus 1.8 Ϯ 0.2 M). Because this assay includes a preincubation phase in which PRMT6, C21, and either SAM or AcH4-21 are incubated for 10 min prior to the addition of the reciprocal substrate, the lack of an effect on the observed IC 50 values was somewhat surprising because if SAM is required for binding to the peptide substrate, as would be expected for an ordered mechanism, then the IC 50 of C21, which is a peptide substrate mimic, should be significantly higher if SAM is absent during the preincubation phase. Although we have not completed a thorough kinetic analysis of the mechanism by which C21 inhibits PRMT6, this finding appears to be inconsistent with previous reports that PRMT6 uses an ordered kinetic mechanism, in which SAM binds prior to the peptide. Therefore, we reinvestigated the kinetic mechanism of PRMT6.
Initial Velocity Studies-The previous assignment of an ordered mechanism (22) was based on experiments with the R1 peptide and a MMA-containing derivative, R1-MMA, which are relatively poor substrates for PRMT6 (Table 1) . Because the use of a poor substrate can make a random mechanism appear ordered, we initially determined the kinetic mechanism of PRMT6 using the AcH4-21R 3 MMA peptide, which is a significantly better (ϳ35-fold) PRMT6 substrate (Table 1) . Subsequently, these experiments were repeated with the R1-MMA peptide. The MMA-containing peptides, AcH4-21R 3 MMA and R1-MMA, were used to carry out the initial experiments because these peptides are only subject to one round of methylation. The experiments were then repeated with the unmethylated peptides.
For the initial velocity studies, the peptide substrate was varied at different fixed concentrations of the methyl donor SAM, and double-reciprocal plots were obtained. For either the AcH4-21R 3 MMA or R1-MMA peptide, an intersecting pattern of lines was observed (Fig. 1, A and B; and Table 2 ). An intersecting line pattern was also observed when SAM was varied at fixed peptide concentrations (Table 2 ). These patterns indicate that PRMT6 utilizes a sequential or ternary complex mechanism in which both substrates must be bound to the enzyme to facilitate methyl transfer. Additionally, the fact that the lines do not intersect on the ordinate indicates that PRMT6 does not use a rapid equilibrium ordered mechanism (see the magnification of the region in Fig. 2B near the ordinate in Fig. 2C ). Note that a similar pattern of intersecting lines was observed when the same experiments were carried out with the unmethylated peptides, AcH4-21 and R1 (Table 2) .
Product Inhibition Studies-Product inhibition studies were next used to determine the order of substrate binding and product release in the PRMT6-catalyzed reaction. The product inhibitors used for these studies were SAH and the appropriate ADMA-containing peptide, AcH4-21R 3 ADMA or R1-ADMA. First, when AcH4-21R 3 MMA was assayed at different concentrations of AcH4-21R 3 ADMA and a fixed concentration of SAM, a competitive pattern of inhibition was observed ( Fig. 2A and Table 3 ). Similarly, when R1-MMA was tested as the varied substrate, R1-ADMA acted as a competitive inhibitor (Table 4) . By definition, a competitive inhibitor is a compound that directly competes with a varied substrate for enzyme binding; hence, the AcH4-21R 3 MMA and R1-MMA peptides bind to the same form of PRMT6 as their respective dimethylated products. In contrast, when SAM was the varied substrate at subsaturating fixed concentrations of either the AcH4-21R 3 MMA (Fig. 2B) or R1-MMA peptide, AcH4-21R 3 ADMA and R1-ADMA acted as noncompetitive inhibitors (Tables 3  and 4 ). This inhibition pattern is expected because SAM does not bind to the same form of the enzyme as the ADMA-containing product and because the two binding events are separated by a reversible step. However, when these experiments were repeated at saturating concentrations (100 ϫ K m ) of the AcH4-21R 3 MMA peptide, no inhibition was observed when SAM was varied at 50, 250, and 500 M AcH4-21R 3 ADMA (Fig.  2C and Table 3 ). Note that the parallel experiment could not be performed with R1-MMA because the K m of this peptide (45 Ϯ 11 M) is much greater than that of AcH4-21R 3 MMA (1.53 Ϯ 0.34 M) and because the high concentrations of R1-MMA required to carry out the experiment are difficult to achieve due to solubility issues with this very hydrophobic peptide. Also note that reciprocal experiments with SAM were not performed because [methyl- 14 C]SAM is used as the methyl donor in these experiments, and it is not feasible to achieve the required concentrations with this compound and maintain the sensitivity of the assay.
Product inhibition experiments with SAH were performed next. When either AcH4-21R 3 MMA or R1-MMA was assayed in the presence of increasing concentrations of SAH at a constant concentration of SAM, SAH acted as a noncompetitive inhibitor (Fig. 3A and Tables 3 and 4) . On the other hand, SAH acted as a competitive inhibitor when SAM was the varied substrate and the concentration of either of the two peptides was fixed at a non-saturating concentration (Fig. 3B and Tables 3  and 4 ). When the AcH4-21R 3 MMA peptide concentration was increased to saturating levels (i.e. 500 M) and SAM remained the varied substrate, SAH still exhibited a competitive pattern of inhibition (Fig. 3C) . Similar results were obtained for the unmethylated peptide substrates, R1 and AcH4-21 (supplemental Tables S1 and S2 ). In total, the product inhibition patterns are consistent with both a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes and a Theorell-Chance mechanism; the latter mechanism is a special case of an ordered mechanism in which the ternary complex forms only transiently.
Dead-end Analog Studies-To differentiate between these two mechanisms, dead-end analog studies were carried out. The dead-end analogs used in these studies were sinefungin, a SAM analog that contains an amine in place of the methyl group, and two peptide derivatives that contain lysine residues in place of the substrate arginine, AcH4-21R 3 K and R1-R 6 K. Note that these peptides are not methylated by PRMT6 above background levels (Table 1) , which indicates that they are suitable for use as dead-end analogs of PRMT6.
The results of these experiments show that the AcH4-21R 3 K peptide acted as a competitive inhibitor when AcH4-21R 3 MMA was varied at a fixed concentration of SAM (Fig. 4A and Table 3 ). The R1-R 6 K peptide also acted as a competitive inhibitor when R1-MMA was the varied substrate (Table 4) . When SAM was the varied substrate, noncompetitive inhibition patterns were observed for both AcH4-21R 3 K and R1-R 6 K at subsaturating levels of the AcH4-21R 3 MMA and R1-MMA peptides, respectively ( Fig. 4B and Tables 3 and 4) . In contrast, no inhibition was observed when SAM was tested as the varied substrate at saturating levels of the AcH4-21R 3 MMA peptide (Table 3 ).
When sinefungin was tested as a dead-end analog at a fixed concentration of SAM and AcH4-21R 3 MMA was the varied substrate, a noncompetitive pattern of inhibition was observed ( Fig. 5A and Table 3 ). Sinefungin also acted as a noncompetitive inhibitor when R1-MMA was the varied substrate (Table 4) . Identical results were obtained with the unmethylated peptides, AcH4-21 and R1 (supplemental Tables S1 and S2). For the converse experiments, in which SAM was the varied substrate FIGURE 2. Product inhibition studies with AcH4-21R 3 ADMA. A, competitive inhibition was observed when AcH4-21R 3 MMA was the varied substrate, SAM was the fixed substrate (15 M), and AcH4-21R 3 ADMA was the product inhibitor. B, noncompetitive inhibition was observed when SAM was the varied substrate, AcH4-21R 3 MMA was the fixed substrate (10 M), and AcH4-21R 3 ADMA was the product inhibitor. C, no inhibition was observed when SAM was the varied substrate, AcH4-21R 3 MMA was the fixed substrate (500 M), and AcH4-21R 3 ADMA was the product inhibitor.
and the concentrations of AcH4-21R 3 MMA and R1-MMA were fixed at subsaturating levels, sinefungin acted as a competitive inhibitor (Fig. 5B) , and when the concentration of AcH4-21R 3 MMA was increased to a saturating level, the pattern of inhibition remained competitive (Fig. 5C ).
DISCUSSION
A number of histone-modifying enzymes, including the PRMTs, histone deacetylases, protein arginine deiminases, histone acetyltransferases, and lysine methyltransferases, have emerged as potential therapeutic targets for a wide range of diseases, including cancer, heart disease, rheumatoid arthritis, colitis, and lupus (25, 26) , although, in all cases, the therapeutic potential of targeting these enzymes has not been validated. Inhibitors targeting the histone deacetylases have been approved for the treatment of at least a subset of cancers, including cutaneous T-cell lymphoma (26) . Additionally, we have shown that protein arginine deiminase inhibition decreases disease severity in mouse models of rheumatoid arthritis and colitis (27, 28) . Given these precedents, we and others have initiated programs to develop inhibitors targeting the PRMTs (19, 29, 30) . Recently, we described C21 as the first irreversible PRMT inhibitor. This compound, denoted C21, is quite selective for PRMT1 versus PRMT3 and PRMT4 but only modestly selective for PRMT6. To account for the fact that C21 inhibits PRMT6 equally well in IC 50 assays regardless of whether the inhibitor is preincubated with the enzyme in the absence or presence of SAM, we reinvestigated the kinetic mechanism of this enzyme because such a result appears to be inconsistent with a previous report (22) indicating that PRMT6 uses an ordered mechanism. Consistent with the previous report, the results of our own initial velocity studies show an intersecting line pattern, demonstrating that PRMT6 uses a sequential mechanism in which both substrates, SAM and the peptide, bind to the enzyme to form a ternary complex prior to methyl transfer. However, the results of our product and dead-end analog inhibition studies indicate that PRMT6 uses a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes (Scheme 2).
The previous report of an ordered mechanism (22) suggested that SAM binds prior to the peptide substrate, methyl transfer occurs, and then the methylated peptide and SAH are released in that order (Scheme 1). The assignment of this mechanism was based solely on the product inhibition patterns afforded by the R1-ADMA peptide and SAH. Of note, SAH was reported to act as a competitive inhibitor when SAM was the varied substrate and a noncompetitive inhibitor when the R1-MMA peptide was the varied substrate. When the other product inhibitor, R1-ADMA, was tested, it exhibited a noncompetitive pattern of inhibition when either peptide or SAM was the varied substrate. Although these results are consistent with the predicted inhibition patterns for the steady-state ordered mechanism described above, the data for the AcH4-21R 3 -ADMA and R1-ADMA peptides are inconsistent with our own. Specifically, we observed that both ADMA-containing peptides act as competitive inhibitors of the PRMT6-catalyzed reaction when the corresponding monomethylated peptides are the varied substrate ( Fig. 2A and Tables 3 and 4) . Furthermore, we observed no inhibition when SAM was the varied substrate and AcH4-21R 3 ADMA was the product inhibitor at saturating amounts of the AcH4-21R 3 MMA peptide (Fig. 2C) ; an uncompetitive pattern of inhibition is expected for the ordered mechanism described by Lakowski and Frankel (22) .
Although these inhibition patterns are not consistent with that specific ordered mechanism, they are consistent with both a Theorell-Chance mechanism and a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes. To differentiate between these two remaining mechanisms and to confirm further that PRMT6 does not use a steady-state ordered mechanism, we performed dead-end analog inhibition studies. The fact that uncompetitive inhibition was not observed with either the AcH4-21R 3 K peptide or sinefungin, under any condition, rules out the Theorell-Chance mechanism. The data obtained with the AcH4-21R 3 K peptide also rule out the ordered mechanism described above. This is the case because a noncompetitive pattern of inhibition is expected for an ordered mechanism if the inhibitor can bind to both the EA and EQ forms of the enzyme, whereas we have shown that the Lyscontaining dead-end inhibitor peptides acted as competitive inhibitors when the corresponding peptide was used as the varied substrate (Fig. 4A) .
When SAM was the varied substrate and the AcH4-21R 3 K peptide was tested as the dead-end analog, a noncompetitive pattern of inhibition was observed with subsaturating levels of the MMA-containing peptide (Fig. 4B) . In contrast, no inhibition was noted when the concentration of AcH4-21R 3 MMA was increased to saturating levels (Fig. 4C) . Both of these results also contradict the predicted inhibition patterns dictated by an ordered mechanism. Uncompetitive inhibition is expected under both conditions. This is the case because the AcH4-21R 3 K peptide binds after SAM and decreases the pool of enzyme available for binding to SAM, and this outcome will occur regardless of the peptide concentration. In contrast, our results show no inhibition at high concentrations of the substrate peptide, which is expected for a random mechanism because the dead-end peptide analog is effectively out-competed by the substrate peptide. Thus, the data indicate that, like PRMT1 (17), PRMT6 utilizes a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes.
As stated above, it is possible that the use of a poor substrate could make a random mechanism appear ordered. However, the results obtained when the R1-R 6 K peptide was used as the dead-end analog are identical to those obtained with the AcH4-21R 3 K peptide (Tables 3 and 4) . Identical patterns of inhibition were also obtained for the unmethylated substrates, i.e. the AcH4-21 and R1 peptides (supplemental Tables S1 and S2). A, noncompetitive inhibition was observed when AcH4-21R 3 MMA was the varied substrate, SAM was the fixed substrate (15 M), and SAH was the product inhibitor. B, competitive inhibition was observed when SAM was the varied substrate, AcH4-21R 3 MMA was the fixed substrate (10 M), and SAH was the product inhibitor. C, competitive inhibition was observed when SAM was the varied substrate, AcH4-21R 3 MMA was the fixed substrate (500 M), and SAH was the product inhibitor.
Thus, regardless of the peptide substrate tested, PRMT6 uses a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes. Although it is difficult to speculate about why FIGURE 4. Dead-end analog inhibition studies with AcH4-21R 3 K. A, competitive inhibition was observed when AcH4-21R 3 MMA was the varied substrate, SAM was the fixed substrate (15 M), and AcH4-21R 3 K was the deadend analog inhibitor. B, noncompetitive inhibition was observed when SAM was the varied substrate, AcH4-21R 3 MMA was the fixed substrate (10 M), and AcH4-21R 3 K was the dead-end analog inhibitor. C, no inhibition was observed when SAM was the varied substrate, AcH4-21R 3 MMA was the fixed substrate (500 M), and AcH4-21R 3 K was the dead-end analog inhibitor. FIGURE 5. Dead-end analog inhibition studies with sinefungin. A, noncompetitive inhibition was observed when AcH4-21R 3 MMA was the varied substrate, SAM was the fixed substrate (15 M), and sinefungin was the deadend analog inhibitor. B, competitive inhibition was observed when SAM was the varied substrate, AcH4-21R 3 MMA was the fixed substrate (10 M), and sinefungin was the dead-end analog inhibitor. C, competitive inhibition was observed when SAM was the varied substrate, AcH4-21R 3 MMA was the fixed substrate (500 M), and sinefungin was the dead-end analog inhibitor.
we observed a random mechanism, whereas Lakowski and Frankel (22) observed an ordered mechanism, we again note that the previous assignment was based solely on the product inhibition patterns afforded by the R1-ADMA peptide and SAH and that their assignment of an ordered versus random mechanism relied only on one key experiment (i.e. the pattern afforded by the R1-ADMA peptide when SAM was the varied substrate). Thus, our data, which also incorporate the results of dead-end analog inhibition studies, give a higher degree of confidence that the assignment of a random mechanism is correct. This is especially true when one considers that the results were confirmed with multiple peptides. The different assignments may be due in part to differences in the assay. Lakowski and Frankel used an MS-based assay, whereas we used a gel-based radioactive assay (16) . A key benefit of our assay is that issues regarding PRMT6 automethylation are circumvented because the products are separated from other reaction substituents by SDS-PAGE and can be reproducibly quantified by phosphorimaging analysis. Additionally, we note that the overall quality of the double-reciprocal plots provided in the previous study are relatively poor and that the authors were unable to interpret the results of the analogous experiments performed with the R1 peptide (22) .
CONCLUSION
The work described herein demonstrates that PRMT6 utilizes a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes to catalyze the methylation of the histone H4-based substrates AcH4-21 and AcH4-21-MMA and the fibrillarin-based substrates R1 and R1-MMA. Although PRMT6 displays limited processivity with either the AcH4-21 or R1 peptide (data not shown), the fact that this kinetic mechanism includes an EBQ (or enzyme⅐SAM⅐AcH4-21-MMA) complex, which can go on to form the dimethylated product, suggests that PRMT6-interacting proteins could modulate the processivity of the enzyme to increase the dimethylation of specific arginine residues. Finally, the assignment of a rapid equilibrium random mechanism with dead-end EAP and EBQ complexes is consistent with our previous report demonstrating that PRMT1 utilizes the same mechanism with AcH4-21 and AcH4-21-MMA (17) .
With regard to inhibitor development, these results are significant because they suggest that high throughput screens designed to identify inhibitors targeting the peptide-binding pocket on PRMT6 need not include SAM in the assay buffer. In the future, these studies set the stage for characterizing the substrate specificity of PRMT6 and identifying the factors that regulate PRMT6 activity. Information from these studies will also undoubtedly aid our effort to develop inhibitors with increased selectivity for both PRMT1 and PRMT6, and ultimately, the increased understanding of this enzyme and the PRMT family will facilitate future investigations of the in vivo activity of this enzyme.
